# Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Source: https://onco.cc/trials/nct04747236/  
OnCo record `nct04747236` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Azacitidine, Romidepsin, Belinostat, Pralatrexate and Gemcitabine in Peripheral T-cell lymphomas, run by University of Virginia, now recruiting.

## Summary

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL is a phase 2 interventional study registered as NCT04747236 by University of Virginia, with 50 participants planned, started 2021-02-19 and due to reach its primary completion in 2028-06-02. Interventions recorded: Azacytidine, Romidepsin, Belinostat, Pralatrexate, Gemcitabine. Conditions recorded: PTCL.

Linked to the drug Romidepsin because the registry names it among its interventions and Peripheral T-cell lymphomas among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04747236
- Phase: 2
- Setting: A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
- Sponsor: University of Virginia
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT04747236: https://clinicaltrials.gov/study/NCT04747236

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Belinostat](https://onco.cc/drugs/belinostat/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Pralatrexate](https://onco.cc/drugs/pralatrexate/), [Romidepsin](https://onco.cc/drugs/romidepsin/)

---
JSON: https://onco.cc/api/v1/entities/nct04747236.json